FDA Questions Accelerated Approval For AstraZeneca’s Olaparib In Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee will consider whether the first-in-class PARP inhibitor should come to market on the basis of Phase II data in a subgroup of patients or await results from an ongoing confirmatory study. Agency cites “uncertainties” about validity and magnitude of effect seen in the Phase II trial.
You may also be interested in...
AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks
Olaparib and TC-5214 development setbacks at AstraZeneca lead to $380 million charge in the fourth quarter, with core EPS likely at the bottom of the expected range.
Moderna’s Pediatric COVID Vaccine Packaging Spurs Confusion Concerns From CDC Panel
Discrete packaging for authorized dose in 6-11 year-olds is not yet available, so vaccination providers have to use product from a vial labeled for ‘booster doses only’ in adults. ACIP members unanimously endorse use of the mRNA vaccine in individuals ages 6-17 years but urge manufacturers to move away from relying on color to differentiate formulations.
Acadia’s Nuplazid Needs Another Study For Alzheimer’s Psychosis, US FDA Panel Says
Advisory committee members cited a litany of shortfalls with efficacy data from two existing studies and say a new Phase III trial is needed in a large, ethnically and racially diverse population of Alzheimer’s disease psychosis patients.